200405 - An observational retrospective database analysis to estimate the risk of Multiple Sclerosis (MS) following vaccination with Arepanrix™ in Manitoba, Canada

First published 01/10/2014

Last updated 23/04/2024

EU PAS number:

EUPAS6817

Study

Finalised

Documents

Study protocol

Initial protocol

200405-protocol-redact

English (344.83 KB - PDF) View document

Study results

gsk-200405-clinical-study-report-redact

English (1.4 MB - PDF) View document

gsk-200405-clinical-study-report-redact_2

English (2.13 MB - PDF) View document

Study report

Other information

Secondary tabs